



SolAeroMed Inc.
Unit 2, Research Transition Facility
3535 Research Road N.W.
Calgary, Alberta, Canada T2L 2K8

Email: info@solaeromed.com

SolAeroMed Inc Investment Announcement: \$7.50 share with warrant

SolAeroMed management announces a new financing round at a \$7.50 share subscription, with each share having a warrant which entitles purchase of the same number of shares, at the same price, valid for 18 months. Through this offering SolAeroMed aims to raise \$500,000. Founders and company insiders have already committed \$150,000. We aim to raise the remaining \$350,000 through existing shareholders and new investors. We aim to close this offer January 31, 2017. Here is a link to this [share subscription](#).

Of interest to Alberta based investors is the recently passed Investment Tax Credit legislation. This program offers an investor tax credit under the *Alberta Corporate Tax Act* equal to 30% of the investment amount in SolAeroMed as an eligible Alberta business.

Monies raised will be used over the coming year to advance R&D milestones and expansion of our patent portfolio, and to provide critical runway to progress partner negotiations.

SolAeroMed is a privately held Alberta based biopharmaceutical company owning two patented drug assets. S1226, our lead therapeutic, is a potent fast acting bronchodilator with a unique mechanism of action and will meet unmet medical needs in the emergency care of asthma, COPD and other respiratory diseases. S1226 has now completed a Phase II proof of concept clinical trial. Our 2nd drug, S1229, is in preclinical development and is formulated to repair dysfunctional lung surfactant in Cystic Fibrosis and other respiratory diseases. Our drug technologies are patented across major markets in Europe, North America and Australasia. Our SolAeroMed company [website](#) summarizes our history, management, drug technologies, and milestone achievements.

If you have interest in learning more, please contact us directly & we'll set up a time to talk. Regardless of your decision to invest, we are happy to share our insight on risks & benefits of our respiratory drug technologies, general understanding of SolAeroMed, and the potential return on your investment.

Look forward to hearing from you.

Sincerely

Dr John Dennis
CEO SolAeroMed Inc